Login
Register
Submit a Paper
Propose a Special lssue
Open Access
REVIEW
CD13: A Key Player in Multidrug Resistance in Cancer Chemotherapy
* Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, P.R. China
† Department of Pharmacy, Qingdao Women and Children’s Hospital, Qingdao, Shandong, P.R. China
Oncology Research 2020, 28(5), 533-540. https://doi.org/10.3727/096504020X15919605976853
Download PDFAbstract
Cancer is one of the most serious diseases that are harmful to human health. Systemic chemotherapy is an optimal therapeutic strategy for the treatment of cancer, but great difficulty has been encountered in its administration in the form of multidrug resistance (MDR). As an enzyme on the outer cell surface, CD13 is documented to be involved in the MDR development of tumor cells. In this review, we will focus on the role of CD13 in MDR generation based on the current evidence.Keywords
CD13; Multidrug resistance (MDR); Drug efflux; Chemotherapy; Reactive oxygen species; Immune suppression
Cite This Article
APA Style
Guo, Q., Li, X., Cui, M., Sun, J., Ji, H. et al. (2020). CD13: A key player in multidrug resistance in cancer chemotherapy. Oncology Research, 28(5), 533-540. https://doi.org/10.3727/096504020X15919605976853
Vancouver Style
Guo Q, Li X, Cui M, Sun J, Ji H, Ni B, et al. CD13: A key player in multidrug resistance in cancer chemotherapy. Oncol Res. 2020;28(5):533-540 https://doi.org/10.3727/096504020X15919605976853
IEEE Style
Q. Guo et al., “CD13: A Key Player in Multidrug Resistance in Cancer Chemotherapy,” Oncol. Res., vol. 28, no. 5, pp. 533-540, 2020. https://doi.org/10.3727/096504020X15919605976853
Copyright © 2020 The Author(s). Published by Tech Science Press.This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Downloads
Citation Tools
